TY - JOUR
T1 - Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants
AU - Bataller, Alex
AU - Loghavi, Sanam
AU - Gerstein, Yoheved
AU - Bazinet, Alexandre
AU - Sasaki, Koji
AU - Chien, Kelly S.
AU - Hammond, Danielle
AU - Montalban-Bravo, Guillermo
AU - Borthakur, Gautam
AU - Short, Nicholas
AU - Issa, Ghayas C.
AU - Kadia, Tapan M.
AU - Daver, Naval
AU - Tang, Guilin
AU - Quesada, Andres
AU - Patel, Keyur P.
AU - Ravandi, Farhad
AU - Fiskus, Warren
AU - Mill, Cristopher P.
AU - Kantarjian, Hagop M.
AU - Bhalla, Kapil
AU - Garcia-Manero, Guillermo
AU - Oran, Betul
AU - DiNardo, Courtney D.
N1 - Publisher Copyright:
© 2023 Wiley Periodicals LLC.
PY - 2023/11
Y1 - 2023/11
N2 - DDX41 is the most frequently mutated gene in myeloid neoplasms associated with germline predisposition including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We analyzed 3795 patients with myeloid neoplasms and identified 151 (4%) with DDX41 variants and a diagnosis of AML (n = 96), MDS (n = 52), and chronic myelomonocytic leukemia (n = 3). The most frequent DDX41 variants were the somatic variant p.R525H, followed by the germline variants p.M1I and p.D140fs. Most neoplasms had a normal karyotype (59%) and the most frequent co-mutations were TP53 (16%) and ASXL1 (15%). 30% of patients had no concomitant mutations besides DDX41 mutation. Patients with myeloid malignancies and DDX41 variants responded well to therapy, with an overall response rate for patients with treatment naïve AML and MDS of 87% and 84%, respectively. The median overall survival (mOS) of patients with treatment-naïve AML or MDS was 49 and 71 months, respectively. Patients with AML treated with low-intensity regimens including venetoclax had an improved survival (2-year OS 91% vs. 60%, p =.02) and lower cumulative incidence of relapse compared to those treated without venetoclax (10% vs. 56%, p =.03). In the 33% of patients receiving hematopoietic stem cell transplantation, the 2-year OS was 80% and 85% for AML and MDS, respectively.
AB - DDX41 is the most frequently mutated gene in myeloid neoplasms associated with germline predisposition including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We analyzed 3795 patients with myeloid neoplasms and identified 151 (4%) with DDX41 variants and a diagnosis of AML (n = 96), MDS (n = 52), and chronic myelomonocytic leukemia (n = 3). The most frequent DDX41 variants were the somatic variant p.R525H, followed by the germline variants p.M1I and p.D140fs. Most neoplasms had a normal karyotype (59%) and the most frequent co-mutations were TP53 (16%) and ASXL1 (15%). 30% of patients had no concomitant mutations besides DDX41 mutation. Patients with myeloid malignancies and DDX41 variants responded well to therapy, with an overall response rate for patients with treatment naïve AML and MDS of 87% and 84%, respectively. The median overall survival (mOS) of patients with treatment-naïve AML or MDS was 49 and 71 months, respectively. Patients with AML treated with low-intensity regimens including venetoclax had an improved survival (2-year OS 91% vs. 60%, p =.02) and lower cumulative incidence of relapse compared to those treated without venetoclax (10% vs. 56%, p =.03). In the 33% of patients receiving hematopoietic stem cell transplantation, the 2-year OS was 80% and 85% for AML and MDS, respectively.
UR - http://www.scopus.com/inward/record.url?scp=85169705493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85169705493&partnerID=8YFLogxK
U2 - 10.1002/ajh.27070
DO - 10.1002/ajh.27070
M3 - Article
C2 - 37665752
AN - SCOPUS:85169705493
SN - 0361-8609
VL - 98
SP - 1780
EP - 1790
JO - American journal of hematology
JF - American journal of hematology
IS - 11
ER -